Tejal Somvanshi
On August 21, 2026, Vitruvias Therapeutics announced a voluntary recall of Thyroid Tablets USP 30 mg, Lot 504950. The U.S. FDA officially published the recall notice on August 24, identifying a critical safety issue: pharmaceutical potency variation.
The affected medication combines levothyroxine (synthetic T4) and liothyronine (synthetic T3)—the two active thyroid hormones. Testing revealed that tablets in Lot 504950 contained higher concentrations than labeled, creating risk of drug-induced hyperthyroidism for patients taking the recalled lot.
The pharmacy distribution window spanned January 31 through September 30, 2025—nationwide. This means affected medications could appear on pharmacy shelves across the entire United States. The recall specifically applies only to Lot 504950; other lots of the same medication remain unaffected.
Certain populations face elevated risk from this potency variation. Pregnant women, elderly patients, and children require careful thyroid dosing; any increase in hormone levels can trigger cardiac complications. The FDA’s MedWatch system allows patients and healthcare providers to report adverse effects directly, creating a safety feedback loop.
The company emphasizes one critical safety instruction: patients should not discontinue thyroid medication abruptly. Sudden cessation interrupts hormone supply to the body, potentially triggering acute hypothyroidism—a serious condition requiring immediate medical attention. Patients with Lot 504950 should contact their healthcare provider for guidance on replacement medication and transition protocols.
Contact information for Vitruvias includes the company safety email (safety@vitruvias.com) and phone line: (256) 239-9373 (Monday–Friday, 9am–5pm Central Time). For medication lots not affected by the recall, patients should continue following their prescriber’s instructions without interruption.
